Actively Recruiting
South Africa Smoking Cessation and Engagement in HIV/TB Care Care
Led by Massachusetts General Hospital · Updated on 2026-04-06
86
Participants Needed
1
Research Sites
115 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
B
Boston University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings.
CONDITIONS
Official Title
South Africa Smoking Cessation and Engagement in HIV/TB Care Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 or older
- Willing and able to provide written informed consent
- Living with HIV and on antiretroviral therapy (ART) and/or within 1 month of starting or restarting TB treatment confirmed by positive GeneXpert test or sputum culture
- Daily smoker of more than 5 cigarettes per day
- Motivated to quit smoking (score above 5 out of 10) or have had a quit attempt lasting more than 24 hours in the past year
You will not qualify if you...
- Habitual use of other tobacco products
- Current untreated or unstable mental health condition (e.g., psychosis, bipolar disorder)
- Currently using other smoking cessation medications not part of the study
- Received cognitive behavioral therapy for smoking cessation within the past year
- Diagnosed with extra-pulmonary or drug-resistant tuberculosis (MDR or XDR) based on medical records
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Cape Town
Rondebosch, South Africa, 7700
Actively Recruiting
Research Team
C
Conall O'Cleirigh, PhD
CONTACT
B
Brianna A Estrada, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here